HIV-1-associated encephalopathy and myelopathy

被引:5
|
作者
Eggers, C [1 ]
机构
[1] Univ Hamburg, Krankenhaus Eppendorf, Neurol Klin, D-20246 Hamburg, Germany
来源
NERVENARZT | 2000年 / 71卷 / 08期
关键词
HIV-1; infection; encephalopathy; dementia;
D O I
10.1007/s001150050646
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
HIV-1-associated encephalopathy (HIVE) remains an important manifestation of advanced HIV infection despite recent progress in antiretroviral therapy. This is in part due to particular pharmacological and virological characteristics of the central nervous system (CNS). HIVE is characterized by a,,subcortical" dementia with psychomotor slowing as well as memory and concentration deficits. An invariable finding are deficits of central motor function. Pathogenetically, an enhanced viral replication in immunocompetent CNS cells is believed to be a requirement. This leads to neurotoxic effects directly elicited by viral products as well as indirectly by the immune response to virus infection. HIV-1 myelopathy (HIVM) is the other CNS manifestion of late HIV infection. The present consensus paper recommends diagnostic and therapeutic procedures in HIVE and HIVM and outlines the current research.
引用
收藏
页码:677 / 684
页数:8
相关论文
共 50 条
  • [21] HIV-1-Associated Atherosclerosis Unraveling the Missing Link
    Kearns, Alison
    Gordon, Jennifer
    Burdo, Tricia H.
    Qin, Xuebin
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (25) : 3084 - 3098
  • [22] Role of IL-15 in HIV-1-associated hypergammaglobulinaemia
    Kacani, L
    Stoiber, H
    Dierich, MP
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1997, 108 (01): : 14 - 18
  • [23] HIV-1-associated dementia: A metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes
    Anderson, E
    Zink, W
    Xiong, HG
    Gendelman, HE
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 : S43 - S54
  • [24] Strategies in the treatment of HIV-1-associated adipose redistribution syndromes
    Gutierrez, Maria del Mar
    Mateo, Gracia
    Domingo, Pere
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (12) : 1871 - 1884
  • [25] Timing of Antiretroviral Therapy for HIV-1-Associated Tuberculosis REPLY
    Blanc, Francois-Xavier
    Laureillard, Didier
    Goldfeld, Anne E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (05): : 475 - 475
  • [26] Oligodendrocyte Injury and Pathogenesis of HIV-1-Associated Neurocognitive Disorders
    Liu, Han
    Xu, Enquan
    Liu, Jianuo
    Xiong, Huangui
    BRAIN SCIENCES, 2016, 6 (03)
  • [27] Microglia: The Real Foe in HIV-1-Associated Neurocognitive Disorders?
    Borrajo Lopez, Ana
    Aranzazu Penedo, Maria
    Rivera-Baltanas, Tania
    Perez-Rodriguez, Daniel
    Alonso-Crespo, David
    Fernandez-Pereira, Carlos
    Manuel Olivares, Jose
    Carlos Agis-Balboa, Roberto
    BIOMEDICINES, 2021, 9 (08)
  • [28] Is PPARγ a Prospective Player in HIV-1-Associated Bone Disease?
    Cotter, Eoin J.
    Mallon, Patrick W.
    Doran, Peter P.
    PPAR RESEARCH, 2009, 2009
  • [29] Potentiation of excitotoxicity in HIV-1-associated Dementia and the significance of glutaminase
    Erdmann, Nathan B.
    Whitney, Nicholas P.
    Zheng, Jialin
    CLINICAL NEUROSCIENCE RESEARCH, 2006, 6 (05) : 315 - 328
  • [30] NEUROBEHAVIORAL AND NEUROIMAGING CORRELATIONS IN HIV-1-ASSOCIATED DEMENTIA COMPILER
    ORTEGO, JN
    CHANG, L
    MILLER, BL
    OROPILLA, G
    MEYER, H
    SATZ, P
    MENA, I
    NEUROLOGY, 1994, 44 (04) : A248 - A248